On June 2, RemeGen (09995.HK) fell 5.48% in regular trading to HK$74.15 per share, with trading volume of approximately HK$88.02 million, extending the prior session's sharp decline as US-China biotech regulatory headwinds intensify.

On the policy front, US legislators recently proposed incorporating biotechnology into the COINS Act's regulatory scope, restricting American capital flows into Chinese innovative pharma companies. Simultaneously, market rumors suggest Chinese regulators may impose pre-approval requirements on overseas BD transactions for domestic drug developers. This dual-sided regulatory barrier directly undermines the core valuation logic for the sector's internationalization thesis. Industry experts have cautioned that policy should be handled prudently to avoid creating the impression of being blocked externally while constrained domestically.

At the company level, Eastern Securities recently reduced its RemeGen holdings by 160,000 shares at an average price of approximately HK$84.83, while related ETF funds have seen consecutive days of net outflows. The broader Biotechnology sector is under broad selling pressure, with peers including 3SBIO down 7.72%, SKB Bio down 6.89%, Akeso down 5.09%, Innovent Bio down 4.26%, and BeiGene down 3.5%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)